

Enhancing Reproducibility and Transparency of Research Findings

*107th Meeting of the
Advisory Committee
to the Director*

December 5th, 2013

Lawrence A. Tabak, DDS, PhD
Principal Deputy Director, NIH



Department of Health and Human Services



Background

- Reproducibility and transparency of research findings have been noted as an issue in multiple publications.
 - This is a problem in all areas of research
 - This issue has been observed in both clinical and preclinical research, though NIH focus is preclinical research



The Economist – October 19th

Beware the creeping cracks of bias

Evidence is mounting that research is riddled with systematic errors. Left unchecked, this could erode public trust, warns Daniel Sarewitz.

Believe it or not: how much can we rely on published data on potential drug targets?

Florian Prinz, Thomas Schlange and Khusru Asadullah

Statistical Design Considerations in Animal Studies Published Recently in *Cancer Research*

Kenneth R. Hess

Raise standards for preclinical cancer research

C. Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit.

Why animal research needs to improve

Many of the studies that use animals to model human diseases are too small and too prone to bias to be trusted, says Malcolm Macleod.

False-Positive Psychology: Undisclosed Flexibility in Data Collection and Analysis Allows Presenting Anything as Significant

Helping editors, peer reviewers and authors improve the clarity, completeness and transparency of reporting health research

David Moher^{*1,2}, Iveta Simera³, Kenneth F Schulz⁴, John Hoey⁵ and Douglas G Altman³

Reforming Science: Methodological and Cultural Reforms

Drug targets slip-sliding away

The starting point for many drug discovery programs is a published report on a new drug target. Assessing the reliability of such papers requires a nuanced view of the process of scientific discovery and publication.

Translating animal research into clinical benefit


Poor methodological standards in animal studies mean that positive results may not translate to the clinical domain

Almost 2/3 of 67 in-house projects could not replicate data published by others

Believe it or not: how much can we rely on published data on potential drug targets?

Prinz, Schlange and Asadullah

Bayer HealthCare



Nature Reviews Drug Discovery, 2011; 10:712-713

Adapted from Dr. S. Silberberg, NINDS


Inconsistency in large pharmacogenomic studies

Benjamin Haibe-Kains^{1,2}, Nehme El-Hachem¹, Nicolai Juul Birkbak³, Andrew C. Jin⁴, Andrew H. Beck^{4*}, Hugo J. W. L. Aerts^{5,6,7*} & John Quackenbush^{5,8*}

Two large-scale pharmacogenomic studies were published recently in this journal. Genomic data are well correlated between studies; however, the measured drug response data are highly discordant. Although the source of inconsistencies remains uncertain, it has potential implications for using these outcome measures to assess gene–drug associations or select potential anticancer drugs on the basis of their reported results.

Patients with cancer often exhibit heterogeneous responses to anticancer treatments, and evidence indicates that response is determined in part by patient-specific alterations in the somatic cancer genome and changes in gene expression¹. Cancer cell line studies have long been used to test the efficacy of therapeutic agents and to explore genomic factors associated with drug response^{2,3}. A number of studies have searched for gene expression signatures predictive of response; however, most only tested a limited number of genes, a small panel of drugs, or assayed drug response in a small number of cell lines^{2,4,5}.

Results from two large-scale pharmacogenomic studies—the Cancer



Background (cont.)

- Relevant NIH workshops in 2012
 - NINDS: “Optimizing the Predictive Value of Preclinical Research”, summarized in 11 October 2012 issue of *Nature* (Held in June)
 - NCI: Reproducibility and data standards (Held in September and December)
- NIH Leadership discusses underlying causes and the development of “pilot” interventions in 2013

Possible causes in difficulties reproducing data

- Misconduct - Falsification, Fabrication, or Plagiarism
 - In 2011, the Office of Research Integrity*:
 - Received 240 allegations
 - Opened 12 as cases
 - Misconduct is one cause, but not the focus of this effort

*http://ori.hhs.gov/images/ddblock/ori_annual_report_2011.pdf

Possible causes in difficulties reproducing data


- ~~Misconduct - Falsification, Fabrication, or Plagiarism~~
- “Cartoon biology” – overemphasis on the “exciting, big picture” finding sometimes results in publications leaving out necessary details of experiments performed



Contents lists available at [SciVerse ScienceDirect](#)

NeuroImage

journal homepage: www.elsevier.com/locate/ynimg



Full Length Articles

The secret lives of experiments: Methods reporting in the fMRI literature

Joshua Carp

University of Michigan, Department of Psychology, 530 Church Street, Ann Arbor, MI, 48109, USA

ARTICLE INFO

Article history:

Accepted 3 July 2012

Available online 10 July 2012

Keywords:

fMRI

Methods reporting

Reproducibility

Experimental design

Analysis methods

Statistical power

ABSTRACT

Replication of research findings is critical to the progress of scientific understanding. Accordingly, most scientific journals require authors to report experimental procedures in sufficient detail for independent researchers to replicate their work. To what extent do research reports in the functional neuroimaging literature live up to this standard? The present study evaluated methods reporting and methodological choices across 241 recent fMRI articles. Many studies did not report critical methodological details with regard to experimental design, data acquisition, and analysis. Further, many studies were underpowered to detect any but the largest statistical effects. Finally, data collection and analysis methods were highly flexible across studies, with nearly as many unique analysis pipelines as there were studies in the sample. Because the rate of false positive results is thought to increase with the flexibility of experimental designs, the field of functional neuroimaging may be particularly vulnerable to false positives. In sum, the present study documented significant gaps in methods reporting among fMRI studies. Improved methodological descriptions in research reports would yield significant benefits for the field.

© 2012 Elsevier Inc. All rights reserved.

Possible causes in difficulties reproducing data

- ~~Misconduct – Falsification, Fabrication, or Plagiarism~~
- “Cartoon biology” – overemphasis on the “exciting, big picture” finding sometimes results in publications leaving out necessary details of experiments performed
- Chance – Experiments performed correctly, but without appropriate replication
 - Difficulty in publication of “negative” findings

Possible causes in difficulties reproducing data

- ~~Misconduct – Falsification, Fabrication, or Plagiarism~~
- “Cartoon biology” – overemphasis on the “exciting, big picture” finding sometimes results in publications leaving out necessary details of experiments performed
- Chance – Experiments performed correctly, but without appropriate replication
 - Difficulty in publication of “negative” findings
- Poor experimental design – fundamental quality characteristics not reported/performed (e.g. blinded assessment, randomization, sample size calculations)

Insufficient reporting of methodological approaches is evident for pre-clinical studies

Table 3. Prevalence of selected quality characteristics in other experimental models

	Number of publications	Randomisation (%)	Blinded assessment of outcome (%)	Sample-size calculation (%)
Transgenic stroke studies	157	n/a	3	0
Stroke pathophysiology studies	166	5	18	0
Parkinson's disease	118	12	15	0
Multiple sclerosis	183	2	11	0

Trends Neurosci 2007; 30: 433-439

Deficient reporting is widespread


Journals:

- Cell
- Nature
- Science
- Nature Medicine
- Nature Genetics
- Nature Immunology
- Nature Biotechnology

>500 citations

Translated to human studies

Figure 1. Methodological Quality of Animal Trials (n=76)



Hackam and Redelmeier, *JAMA* 2006; 14: 1731-1732

Courtesy of Dr. S. Silberberg, NINDS

Possible causes in difficulties reproducing data

- ~~Misconduct – Falsification, Fabrication, or Plagiarism~~
- “Cartoon biology” – overemphasis on the “exciting, big picture” finding sometimes results in publications leaving out necessary details of experiments performed
- Chance – Experiments performed correctly, but without appropriate replication
 - Difficulty in publication of “negative” findings
- Poor experimental design – fundamental quality characteristics not reported/performed (e.g. blinded assessment, randomization, sample size calculations)
- Inadequate reporting of resources used

Follow



Download as

[Introduction](#)[Methods](#)[General Considerations](#)[Specific Resource Identification Criteria](#)[Results and Discussion](#)[Conclusions](#)[Supplemental Information](#)

On the reproducibility of science: unique identification of research resources in the biomedical literature

Nicole A. Vasilevsky¹, Matthew H. Brush¹, Holly Paddock², Laura Ponting³, Shreejoy J. Tripathy⁴, Gregory M. LaRocca⁴, Melissa A. Haendel¹

PubMed ID: 24032093

Scientific reproducibility has been at the forefront of many news stories and there exist numerous initiatives to help address this problem. We posit that a contributor is simply a lack of specificity that is required to enable adequate research reproducibility. In particular, the inability to uniquely identify research resources, such as antibodies and model organisms, makes it difficult or impossible to reproduce experiments even where the science is otherwise sound. In order to better

sites. The results of this experiment show that 54% of resources are not uniquely identifiable in publications, regardless of domain, journal impact factor, or reporting requirements. For example, in many cases the organism strain in which the experiment was performed or antibody that was used could not be identified. Our results show that identifiability is a serious problem for reproducibility. Based on these

determine if a resource was uniquely identifiable, and included examining relevant repositories (such as model organism databases, and the Antibody Registry), as well as vendor sites. The results of this experiment show that 54% of resources are not uniquely identifiable in publications, regardless of domain, journal impact factor, or reporting requirements. For example, in many cases the organism strain in which the experiment was performed or antibody that was used could not be identified. Our results show that identifiability is a serious problem for reproducibility. Based on these results, we provide recommendations to authors, reviewers, journal editors, vendors, and publishers. Scientific efficiency and reproducibility depend upon a research-wide improvement of this substantial problem in science today.



1. Differences and chance cause variation
2. No measurement is exact
3. Bias is rife
4. Bigger is usually better for sample size
5. Correlation does not imply causation
6. Regression to the mean can mislead
7. Extrapolating beyond the data is risky
8. Beware the base-rate fallacy
9. Controls are important
10. Randomization avoids bias
11. Seek replication, not pseudoreplication
12. Scientists are humans
13. Significance is significant
14. Separate no effect from non-significance
15. Effect size matters
16. Study relevance limits generalization
17. Feelings influence risk perception
18. Dependencies change the risks
19. Data can be dredged or cherry picked
20. Extreme measurements may mislead

Underlying issues

- Poor training
- Poor evaluation
- Difficulty in publishing negative findings
- Perverse reward incentives

Learned Publishing, 24:95–97
doi:10.1087/20110203

~\$30,000!



Table 1 Monetary reward system in Zhejiang University

Journal classification	Monetary award
<i>Nature or Science</i>	200,000 RMB (first author); decreased by 50% according to the sequence of authors
SCI journals (first author)	
IF < 1	2,000 RMB
$1 \leq \text{IF} < 3$	3,000 RMB
$3 \leq \text{IF} < 5$	4,000 RMB
$5 \leq \text{IF} < 10$	5,000 RMB
IF ≥ 10	14,000 RMB
EI journals (first author)	1,800 RMB
ISTP (first author)	600 RMB

Principles for addressing the underlying issues

- Raise community awareness
- Enhance formal training
- Protect quality of funded and published research with a more systematic review process
- Address issues of pressure and stability for investigators

Trans-NIH actions

- NIH is discussing reproducibility and transparency of research findings with stakeholder communities to alert them to the issues and solicit feedback.
- Office of Intramural Research is creating and will pilot a new module on research integrity, as it relates to experimental biases and study design, to ethics training course required for NIH intramural fellows. This expected to be ready for testing in the Spring.
- Once tested, the Office of Extramural Research will make available on the web and encourage adoption (or equivalent) by extramural training programs for fellows and trainees.

Trans-NIH actions

Implementation of pilots

- NIH will implement pilots to address to key concerns:
 - Evaluate the “scientific premise” of grant applications
 - Develop a checklist to ensure more systematic evaluation of grant applications
 - Determine approaches needed to reduce “perverse incentives”, e.g.
 - Design changes to bio-sketch requirements
 - Longer-term support for investigators
 - Support replication studies

Trans-NIH actions

Implementation of pilots

- NIH will implement pilots to address to key concerns
- Important issues to consider as the pilots developed:
 - One size does not fit all
 - Effects on experienced vs. early-career researchers
 - Costs of additional data
 - Potential added burden to review process

PubMed Commons Blog

Keeping you up to date about PubMed Commons

NCBI Resources

PubMed.gov

US National Library of Medicine
National Institutes of Health



PubMed Commons is a space for authors to comment on any publication. It is a place for constructive criticism and discussion. PubMed Commons is currently in a pilot phase. Comments in PubMed Commons are not indexed in PubMed.

[Guidelines](#)

You are here: NCBI > Literature

GETTING STARTED

[NCBI Education](#)
[NCBI Help Manual](#)
[NCBI Handbook](#)
[Training & Tutorials](#)

[Copyright](#) | [Disclaimer](#) | [Privacy Policy](#)
National Center for Biotechnology Information
8600 Rockville Pike, Bethesda, MD 20894



[Home](#)

[About](#)

[FAQs](#)

PubMed Commons going public soon

Posted on [November 26, 2013](#)



It's been a month since the beta launch of PubMed Commons, the pilot system that enables authors' discussion and sharing of information about publications in PubMed.

The first public version of the PubMed Commons pilot will be released in the coming weeks. All users of PubMed will be able to see and cite comments.

to
ns
ons



Trans-NIH actions (cont.)

- Convene meeting of Study Section Chairs, Board of Scientific Counselors (BSC) Chairs

Trans-NIH actions (cont.)

- Convene meeting of Study Section Chairs, Board of Scientific Counselors (BSC) Chairs
- Invite Journal Editors to meeting to discuss common opportunities

Announcement: R

24 April 2013



PDF



Rights & Permissions

Over the past year, *Nature* has published articles on the reproducibility of published research. The problems arise in laboratories that do not exert sufficient scrutiny over the data and the information for other researchers.

From next month, *Nature* and the *Journal of Neuroscience* will address the problem by improving the way we ensure that key methodological details are disclosed. We will examine statistical methods, for example by including their raw data.

Central to this initiative is a check for the disclosure of technical and statistical details and to encourage referees to comment on them.



Your network for knowledge

Editors' Update is your one-stop online resource to discover more about the latest developments in journal publishing, policies and initiatives that affect you as an editor, as well as other services and support available. Discover and participate in upcoming events and webinars and join in topical discussions with your peers.

Editors' Home - Elsevier.com

Search



Home

About us

Short Communications

Digital Library

Archives

Contact us

home

Short Communications



8 May 2013 9 Comments

Journal Cortex launches Registered Reports

Post a Short Communication

Register here

Download latest issue

Recommend to a friend

Is the pressure of grants to publish driving the rise in unethical practices from authors?

**Neural Stem Cell Culture: Neurosphere generation, microscopical analysis and cryopreservation**

Authors: Laura Pacey KK, Shelley Stead, Jacqueline Gleave A, Kasia Tomczyk, Laurie Doering C

Lab groups: Department of Pathology and Molecular Medicine, McMaster University

**Production of neuron-preferential lentiviral vectors**

Authors: Takashi Torashima, Chiho Koyama, Haruhiro Higashida, Hirokazu Hirai
Lab groups: H. Higashida Lab (Kanazawa Univ)

Associated Publications: CD38 is critical for social behaviour by regulating oxytocin secretion



Your Best Friend for Lab Supplies >

Science jobs from [naturejobs](#)

Chemistry Faculty Position, Drug Discovery
Department, Moffitt Cancer Center
Moffitt Cancer Center



Company Info

At a glance

Elsevier locations

Mission

Senior management

Experts

Subject information

Publishing guidelines

Corporate responsibility

Open access

Universal access

Company history

Annual reports

Press releases

Corporate

Science & Technology

Elsevier Announces Article Retraction from Journal Food and Chemical Toxicology

Share This:

"Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize," by Gilles Eric Séralini et al. has been retracted by the journal Food and Chemical Toxicology

Cambridge, MA, November 28, 2013

Elsevier announces that the article "Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize," by Gilles Eric Séralini et al. has been retracted by the journal Food and Chemical Toxicology.

Food and Chemical Toxicology 50 (2012) 4221–4231

The journal has issued the following retraction:

The journal *Food and Chemical Toxicology* retracted the article "Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize," which was published in this issue of the journal. The article reported data that were not included in the published article and the data it reports, making any public statements regarding this article invalid.

Very shortly after the publication of this article, the authors were informed of the retraction. The authors have accepted the retraction and have agreed to publish a correction in the next issue of the journal. The authors also agreed to publish a statement in the next issue of the journal, acknowledging the retraction and the reasons for it. The authors also agreed to publish a statement in the next issue of the journal, acknowledging the retraction and the reasons for it. The authors also agreed to publish a statement in the next issue of the journal, acknowledging the retraction and the reasons for it.



Contents lists available at SciVerse ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox



Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize

Gilles-Eric Séralini ^{a,*}, Emilie Clair ^a, Robin Mesnage ^a, Steeve Gress ^a, Nicolas Defarge ^a, Manuela Malatesta ^b, Didier Hennequin ^c, Joël Spiroux de Vendômois ^a

^a University of Caen, Institute of Biology, CRIIGEN and Risk Pole, MRSH-CNRS, EA 2608, Esplanade de la Paix, Caen Cedex 14032, France

^b University of Verona, Department of Neurological, Neuropsychological, Morphological and Motor Sciences, Verona 37134, Italy

^c University of Caen, UR ABTE, EA 4651, Bd Maréchal Juin, Caen Cedex 14032, France

ARTICLE INFO

Article history:

Received 11 April 2012

Accepted 2 August 2012

Available online 19 September 2012

Keywords:

GMO

Roundup

NK603

Rat

Glyphosate-based herbicides

Endocrine disrupting effects

ABSTRACT

The health effects of a Roundup-tolerant genetically modified maize (from 11% in the diet), cultivated with or without Roundup, and Roundup alone (from 0.1 ppb in water), were studied 2 years in rats. In females, all treated groups died 2–3 times more than controls, and more rapidly. This difference was visible in 3 male groups fed GMOs. All results were hormone and sex dependent, and the pathological profiles were comparable. Females developed large mammary tumors almost always more often than and before controls, the pituitary was the second most disabled organ; the sex hormonal balance was modified by GMO and Roundup treatments. In treated males, liver congestions and necrosis were 2.5–5.5 times higher. This pathology was confirmed by optic and transmission electron microscopy. Marked and severe kidney nephropathies were also generally 1.3–2.3 greater. Males presented 4 times more large palpable tumors than controls which occurred up to 600 days earlier. Biochemistry data confirmed very significant kidney chronic deficiencies; for all treatments and both sexes, 76% of the altered parameters were kidney related. These results can be explained by the non linear endocrine-disrupting effects of Roundup, but also by the overexpression of the transgene in the GMO and its metabolic consequences.

© 2012 Elsevier Ltd. All rights reserved.

Trans-NIH actions (cont.)

- Convene meeting of Study Section Chairs, Board of Scientific Counselors (BSC) Chairs
- Invite Journal Editors to meeting to discuss common opportunities
- Continue dialogue with stakeholders – professional societies, industry, academics, patient advocacy groups

Extramural Research Community



Reproducibility Initiative receives landmark cancer studies

October 16, 2013 | Posted by Elizabeth in [Science Exchange](#)



[Home](#) [About](#) [Press](#) [Jobs](#) [Contact](#)



Rewarding Reproducible Research



The COS advocates openness, integrity, and reproducibility of scientific research.

For Scientists

COS maintains the Open Science Framework to archive, share, register, and manage the research lifecycle. COS supports the Open Science Collaboration, develops tools to enable open practices, and provides grants for replications and other projects.

[Read more](#)

For Journals, Funders, and Societies

COS supports infrastructure for preregistration and open practices, produces badges to incentivize open practices, maintains back-end tools for journals, and provides grants for open innovations.

[Read more](#)

For Developers

COS supports open source projects for science, connects via API with other services, hires open source developers, and provides grants for new open projects.

[Read more](#)

Complementary NIH efforts

- Ongoing projects separate from and/or complementary to the proposed pilots
 - NIH has and continues to collaborate with the Association for Psychological Science (APS) and the American Psychological Association (APA) on new and enhanced journal reporting standards (e.g., expanded Methods sections, addition of statistical sections).
 - NIA: Supports the Interventions Testing Program, where preclinical studies are conducted with multi-site duplication, rigorous methodology and statistical analysis.

Complementary NIH efforts (cont.)

- Ongoing projects separate from and/or complementary to the proposed pilots
 - NHGRI: Expectations of validation studies are an inherent part of the review of functional genomics studies and bioinformatics tool development.
 - NIDDK: Supports Mouse Metabolic Phenotyping Centers, which provide the scientific community with standardized, high-quality phenotyping services.
 - NINDS: Established a Scientific Rigor Working Group to forge action plans for rigor-focused efforts.



NIH...

Lawrence.Tabak@nih.gov

Turning Discovery Into Health

